Aurinia Pharmaceuticals (NASDAQ:AUPH) Earns “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) in a report issued on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a $10.00 target price on the biotechnology company’s stock.

Separately, HC Wainwright reissued a buy rating and issued a $13.00 price target on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Aurinia Pharmaceuticals has an average rating of Moderate Buy and an average target price of $10.00.

Aurinia Pharmaceuticals Trading Down 0.8 %

Shares of Aurinia Pharmaceuticals stock opened at $7.08 on Monday. Aurinia Pharmaceuticals has a 12-month low of $4.71 and a 12-month high of $10.05. The company has a quick ratio of 4.82, a current ratio of 5.33 and a debt-to-equity ratio of 0.18. The business’s 50 day moving average is $6.15 and its 200-day moving average is $5.58. The stock has a market cap of $1.01 billion, a P/E ratio of -16.47 and a beta of 1.44.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share for the quarter, hitting the consensus estimate of $0.01. Aurinia Pharmaceuticals had a negative return on equity of 11.84% and a negative net margin of 24.31%. The business had revenue of $57.10 million during the quarter, compared to analysts’ expectations of $54.25 million. During the same period last year, the firm posted ($0.08) EPS. The firm’s revenue for the quarter was up 37.6% compared to the same quarter last year. Equities research analysts predict that Aurinia Pharmaceuticals will post 0.13 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Scott Michael Habig sold 18,249 shares of Aurinia Pharmaceuticals stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $5.31, for a total value of $96,902.19. Following the completion of the transaction, the insider now owns 456,338 shares in the company, valued at $2,423,154.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Vermillion & White Wealth Management Group LLC purchased a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter worth $30,000. Tidemark LLC purchased a new position in shares of Aurinia Pharmaceuticals during the fourth quarter worth about $39,000. Banque Cantonale Vaudoise increased its position in shares of Aurinia Pharmaceuticals by 126.6% in the second quarter. Banque Cantonale Vaudoise now owns 9,684 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 5,410 shares during the last quarter. Eagle Asset Management Inc. bought a new stake in Aurinia Pharmaceuticals during the fourth quarter valued at approximately $92,000. Finally, B. Riley Wealth Advisors Inc. purchased a new stake in shares of Aurinia Pharmaceuticals during the 2nd quarter valued at $84,000. 36.83% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.